Dr Mariola Söhngen, CEO, Mologen 00:00:00

Share On Facebook Share On Twitter

Mologen is a German biotech company developing cancer immunotherapies. Their lead product is Lefitolimod (MGN1703) which is being tested in a phase III trial for metastatic colorectal cancer

Recent Videos